Scleroderma
Immunology·MeSH: Scleroderma, Diffuse
Prevalence
200.0 / 100K
8 drugs in development·5 companies·8 clinical trials
Drug Pipeline by Phase
Phase 2(4)
Preclinical(1)
| Drug | Company |
|---|---|
| tmb-003 | TREX WIND-DOWN, INC. (TMBR) |
Unknown(1)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| fcx-013 | Fibrocell Science, Inc. (FCSC) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| qrx008 | Quoin Pharmaceuticals, Ltd. (QNRX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Scleroderma?
BioSniper tracks 8 drugs in development for Scleroderma across 5 companies.
How many clinical trials target Scleroderma?
There are 8 clinical trials targeting Scleroderma tracked by BioSniper.
What is the prevalence of Scleroderma?
The estimated prevalence of Scleroderma is approximately 200.0 per 100,000 population.
Deep-dive into Scleroderma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis